02742nas a2200241   4500008004100000022001400041245010300055210006900158260000800227300001200235490000700247520195100254653001202205653002002217653001402237653001802251653002102269100002302290700002102313700002402334700001902358856012302377       2026                        eng d  a0724-874100aNovel cocrystal of quercetagetin: in vitro and in vivo insights into biopharmaceutical performance0 aNovel cocrystal of quercetagetin in vitro and in vivo insights i  cMAR  a927-9390 v433 a<p>
	Purpose Quercetagetin (QTGN) is a naturally occurring flavonol predominantly sourced from marigold flowers and possesses notable therapeutic potential, including antidiabetic, anticancer, antioxidant, anti-inflammatory, and antiviral properties. However, poor aqueous solubility and in turn bioavailability restrict therapeutic utility of QTGN. Crystal engineering is one of the approaches proven to be fruitful in resolving the solubility issues of many active pharmaceutical ingredients (APIs). Method In the present work, a cocrystal of QTGN using betaine (BET) as coformer viz. Quercetagetin &amp; sdot;betaine &amp; sdot;ethanol (QTGN &amp; sdot;BET &amp; sdot;EtOH) was synthesized using the solvent evaporation method. It was further characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Thermogravimetric analysis (TGA), Powder X-ray diffraction (PXRD), and single crystal XRD (SCXRD). Result FTIR studies confirmed hydrogen bonding between QTGN and BET. PXRD studies showed formation of new crystalline phase. The prepared cocrystal had stoichiometric ratio of 1:1:1 between QTGN, BET, and ethanol forming cocrystal ethanolate and shared robust hydroxyl &amp; ctdot;carboxylate supramolecular synthon as confirmed by TGA and SCXRD, respectively. Equilibrium solubility study and in vitro dissolution study showed a significant improvement (p &lt; 0.0001) in aqueous solubility of QTGN upon its cocrystallization with BET. Furthermore, in vivo pharmacokinetic study revealed a 1.28-fold increase in bioavailability of QTGN when formulated as cocrystal solvate. The prepared cocrystal was found to be stable over a period of six months at 40 degrees C and 75% RH when analyzed using PXRD studies. Conclusion The current work represents a frontier in pharmaceutical formulation, providing a means to fully harness the therapeutic potential of QTGN using cocrystal approach.</p>
10abetaine10aBioavailability10acocrystal10aquercetagetin10aUSP apparatus IV1 aSuryawanshi, Smita1 aShaligram, Parth1 aGonnade, Rajesh, G.1 aPatil, Sharvil  uhttps://library.ncl.res.in/content/novel-cocrystal-quercetagetin-vitro-and-vivo-insights-biopharmaceutical-performance